Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Negligible Impact of Mass Screening and Treatment on Mesoendemic Malaria Transmission at West Timor in Eastern Indonesia: A Cluster-Randomized Trial.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01878357 (Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia), which is not on this map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Pooled it
- A systematic review of sample size estimation accuracy on power in malaria cluster randomised trials measuring epidemiological outcomes.BMC medical research methodology · 2024Pooled it
- Mass Testing and Treatment to Accelerate Malaria Elimination: A Systematic Review and Meta-Analysis.The American journal of tropical medicine and hygiene · 2024Pooled it
- Targeted Testing and Treatment To Reduce Human Malaria Transmission in High-Risk Populations: A Systematic Review.The American journal of tropical medicine and hygiene · 2024Pooled it
- Validation of serological markers of recent exposure toThe Lancet regional health. Western Pacific · 2026Article
- Malaria serology for surveillance, insights into immunity, and vaccine development.Infection and immunity · 2026Review
- Increased Plasmodium falciparum EBA175RIII-V antibody titres despite a 13-month malaria mass testing, treatment, and tracking intervention in a high malaria endemic community in Ghana.Malaria journal · 2025Article
- Shrinking the malaria map in Indonesia: progress of subnational control, elimination, and future strategies.BMC medicine · 2025Review
- Applying novel Plasmodium Vivax serological exposure markers to quantify residual malaria transmission in the Philippines through repeated health facility surveys: the SMaRT study protocol.BMC infectious diseases · 2025Article
- Global trends and burdens of neglected tropical diseases and malaria from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021.BMC public health · 2025Article
- Which diagnostic test to use for Testing and Treatment strategies inLancet regional health. Americas · 2024Article
- Plasmodium vivax serological exposure markers: PvMSP1-42-induced humoral and memory B-cell response generates long-lived antibodies.PLoS pathogens · 2024Article
- A Health Survey Revealing Prevalence of Vector-Borne Diseases and Tuberculosis in Papua New Guinea Defence Force Personnel and Families.The American journal of tropical medicine and hygiene · 2023Article
- Accelerating towardsLancet regional health. Americas · 2023Article
- The Impact of Submicroscopic Parasitemia on Malaria Rapid Diagnosis in Northeastern Tanzania, an Area with Diverse Transmission Patterns.Infectious disease reports · 2022Article
- Developing sero-diagnostic tests to facilitate Plasmodium vivax Serological Test-and-Treat approaches: modeling the balance between public health impact and overtreatment.BMC medicine · 2022Article
- Identifying forms of interventions towards cross border malaria in the Asia-Pacific region: a scoping review protocol.BMJ open · 2022Article
- Assessment of IgG3 as a serological exposure marker forFrontiers in cellular and infection microbiology · 2022Article
- The global burden of Plasmodium vivax malaria is obscure and insidious.PLoS medicine · 2021Article
- Identification of the asymptomatic Plasmodium falciparum and Plasmodium vivax gametocyte reservoir under different transmission intensities.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mass screening and treatment (MST) aims to reduce malaria risk in communities by identifying and treating infected persons without regard to illness. Methods: A cluster-randomized trial evaluated malaria incidence with and without MST. Clusters were randomized to 3, 2, or no MST interventions: MST3, 6 clusters (156 households/670 individuals); MST2, 5 clusters (89 households/423 individuals); and MST0, 5 clusters (174 households/777 individuals). All clusters completed the study with 14 residents withdrawing. In a cohort of 324 schoolchildren (MST3, n = 124; MST2, n = 57; MST0, n = 143) negative by microscopy at enrollment, we evaluated the incidence density of malaria during 3 months of MST and 3 months following. The MST intervention involved community-wide expert malaria microscopic screening and standard therapy with dihydroartemisinin-piperaquine and primaquine for glucose-6 phosphate dehydrogenase-normal subjects. All blood examinations included polymerase chain reaction assays, which did not guide on-site treatment. Results: The risk ratios for incidence density of microscopically patent malaria in MST3 or MST2 relative to that in MST0 clusters were 1.00 (95% confidence interval [CI], .53-1.91) and 1.22 (95% CI, .42-3.55), respectively. Similar results were obtained with molecular analysis and species-specific (P. falciparum and P. vivax) infections. Microscopically subpatent, untreated infections accounted for 72% of those infected. Conclusions: Two or 3 rounds of MST within 3 months did not impact the force of anopheline mosquito-borne infection in these communities. The high rate of untreated microscopically subpatent infections likely explains the observed poor impact. Clinical Trials Registration: NCT01878357.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.